Reduction of mycophenolate mofetil dosage to limit prolonged viral shedding in solid organ transplant recipients with COVID-19: Two case reports

Solid organ transplant (SOT) recipients with coronavirus disease-2019 (COVID-19) experience prolonged viral shedding, and they are forced to stay in the hospital because of the requirement for COVID-19 isolation. Here, we present two cases (lung and renal transplant recipients), wherein the isolatio...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory investigation 2024-01, Vol.62 (1), p.98-101
Main Authors: Murai, Yushi, Sakao, Seiichiro, Kure, Fujihiro, Kawasaki, Takeshi, Maruyama, Michihiro, Suzuki, Hidemi, Yoshino, Ichiro, Suzuki, Takuji
Format: Article
Language:English
Subjects:
COVID-19
Humans
Immunosuppressive Agents
Kidney Transplantation
Lung transplantation
Mycophenolic Acid
Virus Shedding
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid organ transplant (SOT) recipients with coronavirus disease-2019 (COVID-19) experience prolonged viral shedding, and they are forced to stay in the hospital because of the requirement for COVID-19 isolation. Here, we present two cases (lung and renal transplant recipients), wherein the isolation period was shortened by reducing the dosage of mycophenolate mofetil (MMF). Both patients recovered well from COVID-19 pneumonia. This case study suggests that a reduction in MMF dosage may lead to a shorter hospitalization period in SOT recipients with COVID-19.
ISSN:2212-5345
2212-5353
DOI:10.1016/j.resinv.2023.10.006